AstraZeneca pays out $6m to settle US bribery case

Billy Bambrough
Follow Billy
Drugs Giant AstraZeneca Buy Biotechnology Firm
Cambridge-based AstraZeneca is one of the biggest international pharma firms in China (Source: Getty)

AstraZeneca will pay $5.5m (£4.1m) to resolve a foreign bribery probe in the US.

The payment settles an alleged bribery case at the drugmaker’s Chinese and Russian units going back as far as 2005.

The US Securities and Exchange Commission (SEC) claims Astra staff made payments and gave other benefits to state-employed doctors and other healthcare workers, in return for increased prescriptions.

Read more: AstraZeneca's revenue hurt by new US market competition

The SEC said AstraZeneca set up bank accounts in doctors’ names, hired a “collusive travel vendor” who submitted fake or inflated invoices to generate cash to funnel money, and “totally fabricated” conferences to pay out speaker fees despite there being “no meeting date, venue, [nor] subject”.

The regulator said AstraZeneca cooperated with the probe, which factored into the size of the penalty that was assessed against it.

“We are pleased to have resolution of these matters,” the firm said. AstraZeneca is one of the biggest international pharma firms in China, with 45,000 staff.

Read more: One of AstraZeneca's big pipeline drugs just failed a late-stage trial

A recent report from Transparency International found both governments and companies are not doing enough to address corruption, which is sapping $300m from annual healthcare spending.

What you need to know

  1. Peter Stringfellow in his own words: The king of London's nightlife on Theresa May and making money
  2. The shareholders are revolting: Bosses really have received a bloody nose over bonuses this year
  3. Lloyd's of Hong Kong? Insurance boss threatens to quit the City

Related articles